2017. ISOQOL Annual Conference – Are clinical outcome assessment (COA) data important in the evaluation of medicines for the treatment of Alzheimer’s disease approved by the FDA and the EMA?

Anfray C, Emery MP, Perrier LL, Acquadro C. Are clinical outcome assessment (COA) data important in the evaluation of medicines for the treatment of Alzheimer’s disease approved by the FDA and the EMA? Presented at: ISOQOL 24th Conference; October 18-24, 2017; Philadelphia, PA, USA.